ePrints

The role of PARP in DNA repair and its therapeutic exploitation

Lookup NU author(s): Professor Nicola CurtinORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Historically, PARP inhibitors (PARPi) were developed to potentiate the cytotoxic effect of certain chemotherapeutic agents and are currently being investigated in combination with chemotherapy in diverse cancer types. These agents are also radiosensitisers and clinical trials of PARPi with concurrent radiation are required. It has long been recognised that defective DNA repair pathways lead to tumour susceptibility. Recent studies indicate that tumour cells with defective homologous recombination (HR) repair pathways, the classic example being BRCA mutations, are exquisitely sensitive to PARPi. Defects in HR are not restricted to BRCA-associated tumours and other cancer types may be enriched for HR defects and hence susceptible to PARP inhibition. The identification of predictive markers for sensitivity to PARP inhibition is a priority area for research. British Journal of Cancer (2011) 105, 1114-1122. doi:10.1038/bjc.2011.382 www.bjcancer.com (C) 2011 Cancer Research UK

Publication metadata

Author(s): Javle M, Curtin NJ

Publication type: Review

Publication status: Published

Journal: British Journal of Cancer

Year: 2011

Volume: 105

Issue: 8

Pages: 1114-1122

Print publication date: 11/10/2011

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: NATURE PUBLISHING GROUP

URL: http://dx.doi.org/10.1038/bjc.2011.382

DOI: 10.1038/bjc.2011.382

Share